Co-occurrence of Klebsiella variicola and Klebsiella pneumoniae Both Carrying blaKPC from a Respiratory Intensive Care Unit Patient

Huang, Lianjiang; Fu, Li; Hu, Xiaoyan; Liang, Xiaoliang; Gong, Guozhong; Xie, Chunhong; Zhang, Feiyang; Wang, Ying; Zhou, Yingshun

doi:10.2147/idr.s330977

Cited by 5 publications

(2 citation statements)

References 39 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Moreover, K. variicola and K. pneumoniae isolated from the same patient had the different antimicrobial susceptibility profiles for K. variicola was imipenem-susceptible, but K. pneumoniae was resistant. 29,30 However, K. variicola 4717 isolated in this work showed resistance to both imipenem and meropenem. The biofilm formation assay showed K. variicola 4717 was a moderate biofilm producer due to the expression of fimbriae factors, granting it the ability to adhere and colonize.…”

Section: Discussionmentioning

confidence: 59%

Emergence of OXA-484-Producing Klebsiella variicola in China

Ge¹,

Qiao²,

Xu³

et al. 2023

IDR

View full text Add to dashboard Cite

The frequent and inappropriate use of antibiotics has caused a dramatic rise in the number, species, and degree of multi-drug resistant bacteria, making them more prevalent and difficult to treat. In this context, the aim of the present study was to characterize the OXA-484-producing strains isolated from a perianal swab of a patient by using whole-genome analysis. Patients and Methods: In this study, carbapenemase-producing Klebsiella variicola was identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), average nucleotide identity (ANI) and PCR. S1 nuclease pulsed-field gel electrophoresis (S1-PFGE) and Southern blotting were utilized to characterize the plasmid profiles of K. variicola 4717. In particular, WGS was performed to obtain genomic information on this clinical isolate, and assemble all the plasmids of the bla OXA-484 -harboring strain. Results: The antimicrobial susceptibility pattern of K. variicola 4717 revealed that it was resistant to a range of antibiotics, including aztreonam, imipenem, meropenem, ceftriaxone, cefotaxime, ceftazidime, levofloxacin, ciprofloxacin, piperacillin-tazobactam, methylenesulfamer oxazole, amoxicillin-clavulanic acid, cefepime, and tigecycline. Its susceptibility to chloromycin was intermediate, while it was still susceptible to amikacin, gentamicin, fosfomycin, and polymyxin B. The presence of two companion plasmids, p4717_1 and p4717_2, together with a plasmid carrying the bla OXA-484 gene was observed. An in-depth investigation of p4717-OXA-484 uncovered that it is an IncX3-type plasmid and shares a similar segment encoded by IS26. Given the similar genetic background, it was conceivable that bla OXA-484 could have developed from bla OXA-181 through a series of mutations. Conclusion: Herein, we described the first genome sequence of K. variicola strain harbouring the class D β-actamase bla OXA-484 in an Inc-X3-type plasmid. Our work also uncovered the genetic characterization of K. variicola 4717 and the importance of initiating antimicrobial detection promptly.

show abstract

Section: Discussionmentioning

confidence: 59%

Emergence of OXA-484-Producing Klebsiella variicola in China

Ge¹,

Qiao²,

Xu³

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…None of the analyzed K. variicola strains produced carbapenemases, but there are articles in the literature about carbapenemase-positive K. variicola strains that produce NDM, KPC, IMP, or OXA enzymes [36][37][38][39]. Although there are a few reports in the literature assessing the susceptibility of K. variicola isolates to antimicrobials, they did not include fosfomycin or new combinations of β-lactams with β-lactamase inhibitors.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

Sękowska

2024

Antibiotics

View full text Add to dashboard Cite

The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population. Resistance to carbapenems is a significant antimicrobial resistance mechanism, leading to limited therapeutic options. Therefore, the aim of this study was to evaluate the in vitro activity of fosfomycin, colistin, ceftazidime–avibactam, and meropenem–vaborbactam against multidrug-resistant K. pneumoniae complex strains. This study involved 160 strains of Gram-negative rods, comprising 138 K. pneumoniae and 22 K. variicola. The minimal inhibitory concentration of fosfomycin was estimated using the agar dilution method, and for colistin, the microdilution method was employed. Susceptibility to ceftazidime–avibactam and meropenem–vaborbactam was determined using the gradient strip method. All analyzed K. pneumoniae complex isolates produced extended-spectrum β-lactamases, and 60.0% exhibited carbapenemases. The majority of the analyzed strains were susceptible to fosfomycin and colistin (62.5%). Among pandrug-resistant K. pneumoniae complex isolates, the highest susceptibility was observed with colistin (43.9%). Fosfomycin demonstrated good activity against ESβLs- and VIM-positive isolates from this complex. Colistin also exhibited satisfactory in vitro activity against VIM- and KPC-positive isolates from the K. pneumoniae complex. Ceftazidime–avibactam displayed good activity against K. pneumoniae complex strains producing ESβLs, KPC, and OXA enzymes. Additionally, meropenem–vaborbactam showed satisfactory in vitro activity against ESβLs- and KPC-positive isolates from this complex.

show abstract

In Vitro Activity of “Last Chance” Antimicrobials against Klebsiella pneumoniae Complex.

Sękowska

2023

Preprint

View full text Add to dashboard Cite

Klebsiella pneumoniae complex is one of the most commonly isolated bacteria within human infections. These microorganisms are opportunistic pathogens that pose a serious threat to public health due to possibility of transmission in the human population. Resistance to carbapenems is one of the most important antimicrobials resistance mechanisms amongst them. In this situation therapeutic options are limited. Therefore, the aim of this study was to evaluate fosfomycin, colistin, ceftazidime-avibactam and meropenem-vaborbactam in vitro activity against multidrug-resistant K. pneumoniae complex strains. The study involved 160 strains of Gram-negative rods: K. pneumoniae – 138 and K. variicola - 22. Minimal inhibitory concentration of fosfomycin was estimated by agar dilution method and for colistin by microdilution method. The susceptibility to ceftazidime-avibactam and meropenem-vaborbactam was determined by gradient strip method. All of the analysed K. pneumoniae complex isolates produced extended-spectrum beta-lactamases and 60.0% carbapenemases. The most of the analysed strains were susceptible to fosfomycin and colistin (62.5%). Among pandrug-resistant K. pneumoniae complex isolates the most were susceptible to colistin (43.9%). Fosfomycin has good activity against ESBL- and VIM-positive isolates from this complex. In turn, colistin has satisfactory in vitro activity against KPC- and VIM-positive isolates from K. pneumoniae complex. Ceftazidime-avibactam has good activity against K. pneumoniae complex strains producing ESBL, KPC and OXA enzymes. In turn, meropenem-vaborbactam has satisfactory in vitro activity against ESBL- and KPC-positive isolates from this complex.

show abstract

Co-occurrence of Klebsiella variicola and Klebsiella pneumoniae Both Carrying blaKPC from a Respiratory Intensive Care Unit Patient

Cited by 5 publications

References 39 publications

Emergence of OXA-484-Producing Klebsiella variicola in China

Emergence of OXA-484-Producing Klebsiella variicola in China

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

In Vitro Activity of “Last Chance” Antimicrobials against Klebsiella pneumoniae Complex.

Contact Info

Product

Resources

About